SALT LAKE CITY, Feb. 6 /CNW/ -- World Heart Corporation ("WorldHeart",
Nasdaq: WHRT), a pioneer in cardiac assist technologies, announced today that
it has appointed John Alexander ("Alex") Martin as President and CEO. Mr.
Martin also replaced Jal S. Jassawalla on the Board of Directors. Mr. Martin
joins WorldHeart from Edwards Lifesciences where he was President of the North
American Region and Corporate Vice President since 2004. Previously, Alex was
with Cordis Corporation, a Johnson and Johnson (J&J) company, where he served
as Senior Vice President of International and prior to that, Vice President of
Sales and Marketing. At Cordis, he had responsibility for all U.S. coronary
therapeutic and diagnostic device sales and under his leadership the company
experienced significant growth and became the market leader. Alex was
responsible for the launch of the first commercialized drug-eluting stent in
the US while at Cordis.
Before Cordis, Mr. Martin, 55, served in sales, marketing and business
development management positions at several organizations, including C.R.
Bards' USCI division, Cambridge Heart and IMED Corporation. He also served as
Director of the Emergency Medical Services at The Medical Center at Bowling
Green. Mr. Martin earned a bachelor's degree from the University of Kentucky
Jal S. Jassawalla, WorldHeart's President and CEO since 2004 and
co-founder of the original Novacor Medical Corporation, commented that, "I
join WorldHeart's Board of Directors and employees in welcoming Alex to
WorldHeart and the exciting and promising field of circulatory assist
therapy." Mr. Jassawalla will continue in a senior role as Executive Vice
President and Chief Technology Officer. His emphasis will be on research &
development, product strategy, and clinical and regulatory affairs.
"We are pleased to have Alex Martin join WorldHeart," said Michael Estes,
Chair of WorldHeart's Board of Directors. "Alex's extensive background in
medical technologies and long-standing relationships within the cardiovascular
community will be particularly valuable as WorldHeart brings its Levacor
technology into the clinical arena and continues to advance its unique
'mag-lev' technology platform. The Board of Directors is also very pleased
that Jal Jassawalla will continue in his key role as Executive Vice President
About World Heart Corporation
WorldHeart is a developer of mechanical circulatory support systems.
WorldHeart is headquartered in Salt Lake City, Utah with additional facilities
in Oakland, California, USA and Herkenbosch, The Netherlands. WorldHeart's
registered office is in Ottawa, Ontario, Canada.
Any forward-looking statements in this release are made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform Act of 1995
and include all statements regarding WorldHeart's technology platform and
reliance on key executives, as well as other statements that can be identified
by the use of forward-looking language, such as "believes," "feels,"
"expects," "may," "will," "should," "seeks," "plans," "anticipates," or
"intends" or the negative of those terms, or by discussions of strategy or
intentions. Investors are cautioned that all forward-looking statements
involve risk and uncertainties, including without limitation: WorldHeart's
need for additional capital in the future; risks in product development and
market acceptance of and demand for WorldHeart's products; delisting from the
NASDAQ Stock Market if compliance with the listing standards is not regained;
and other risks detailed in WorldHeart's filings with the U.S. Securities and
Exchange Commission, including without limitation its Annual Report on Form
10-KSB/A for the year ended December 31, 2007 and its Quarterly Report on Form
10-Q/A for the quarter ended March 31, 2008 and its Quarterly Reports on Form
10-Q for the quarters ended June 30, 2008 and September 30, 2008.
For further information:
For further information: Mr. David Pellone, +1-510-563-4775, or Ms.
Peggy Allman, +1-510-563-4721, both of World Heart Corporation Web Site: